AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35772665 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 147
Study 35772665 — intervention group
Group type: COMPARATOR
Intervention: Placebo (platinum-based chemotherapy)
Number of subjects: 147
Study 35772665 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib (platinum-based chemotherapy)
Number of subjects: 147
Study 35772665 — intervention group
Group type: COMPARATOR
Intervention: Placebo (non-platinum-based chemotherapy)
Number of subjects: 147
Study 35772665 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib (non-platinum-based chemotherapy)
Number of subjects: 147
Study 33759075 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D deficiency (25OHD deficiency)
Number of subjects: 1812
Study 33759075 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D inadequacy (25OHD inadequacy)
Number of subjects: 1812
Study 35829765 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 160
Study 35829765 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 160
Study 33774848 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin extended-release 1500 mg daily for 26 weeks
Number of subjects: 40
Study 33774848 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo for 26 weeks
Number of subjects: 40
Study 32053828 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 36
Study 32053828 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 36
Study 35044581 — intervention group
Group type: EXPERIMENTAL
Intervention: ICE-guided ablation
Number of subjects: 91
Study 35044581 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopy-only ablation
Number of subjects: 91
Study 32866344 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicolored 3D-printed teeth models
Number of subjects: 0
Study 32866344 — intervention group
Group type: COMPARATOR
Intervention: Standard plastic teeth (control)
Number of subjects: 0
Study 33501595 — intervention group
Group type: EXPERIMENTAL
Intervention: JWH‐018 (75μg/kg bodyweight, average dose 5.52 mg)
Number of subjects: 24
Study 33501595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 33837996 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical counts performed between 8:00 a.m. to 12:00 a.m.
Number of subjects: 70
Study 33837996 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency operations
Number of subjects: 70
Study 33837996 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged procedures
Number of subjects: 70
Study 33837996 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of surgical items
Number of subjects: 70
Study 35083837 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise
Number of subjects: 56
Study 35083837 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 56
Study 33538250 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 460
Study 33538250 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 460
Study 33538250 — intervention group
Group type: EXPERIMENTAL
Intervention: TOs in left main and/or left anterior descending artery
Number of subjects: 460
Study 33877876 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin as an add-on therapy
Number of subjects: 0
Study 33033962 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 0
Study 33033962 — intervention group
Group type: COMPARATOR
Intervention: Ivabradine co-administered with ketoconazole (CYP3A4 inhibitor)
Number of subjects: 0
Study 35460449 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self-help family-based treatment (GSH-FBT)
Number of subjects: 0
Study 35460449 — intervention group
Group type: COMPARATOR
Intervention: Family-based treatment delivered via videoconferencing (FBT-V)
Number of subjects: 0
Study 33130890 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ) chemotherapy
Number of subjects: 98
Study 33130890 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT)
Number of subjects: 98
Study 35274413 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous interferon beta‐1a (sc IFN β‐1a) 44 μg once or three times weekly
Number of subjects: 0
Study 35274413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35985024 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (n = 7) - attended training course, Alzheimer Café, self-help group, in-home visits from volunteer and professional nurse
Number of subjects: 14
Study 35985024 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 7) - attended standard intervention
Number of subjects: 14
Study 33070244 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping and Promoting Strength (CAPS)
Number of subjects: 113
Study 33070244 — intervention group
Group type: COMPARATOR
Intervention: Information-monitoring (IM)
Number of subjects: 113
Study 34793724 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding exclusivity group with low initial probability (n = 60, 49%)
Number of subjects: 122
Study 34793724 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding exclusivity group with greater initial probability (n = 62, 51%)
Number of subjects: 122
Study 34793724 — intervention group
Group type: EXPERIMENTAL
Intervention: PIM group with greater probability of endorsing PIM (n = 41, 34%)
Number of subjects: 122
Study 34793724 — intervention group
Group type: EXPERIMENTAL
Intervention: PIM group with low probability of endorsing PIM (n = 81, 66%)
Number of subjects: 122
Study 32024852 — intervention group
Group type: EXPERIMENTAL
Intervention: NaHCO3 (up to 100 mg·kg‐1)
Number of subjects: 51
Study 33576936 — intervention group
Group type: EXPERIMENTAL
Intervention: 165 μg PEGylated exenatide
Number of subjects: 36
Study 33576936 — intervention group
Group type: EXPERIMENTAL
Intervention: 330 μg PEGylated exenatide
Number of subjects: 36
Study 33576936 — intervention group
Group type: EXPERIMENTAL
Intervention: 660 μg PEGylated exenatide
Number of subjects: 36
Study 32618165 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic scaler with ozonated water (Ozonline®)
Number of subjects: 10
Study 32618165 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonic scaler (Control)
Number of subjects: 10
Study 35365535 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive TDM combined PK dashboard-driven infliximab dosing
Number of subjects: 0
Study 35365535 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) infliximab therapy
Number of subjects: 0
Study 32332458 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg)
Number of subjects: 36
Study 32332458 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (5 mg/d for 15 days)
Number of subjects: 36
Study 32332458 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (10 mg/d for 15 days)
Number of subjects: 36
Study 32332458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 33152448 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 doses of 40 mg/m2 of prednisone on alternate days (short arm)
Number of subjects: 78
Study 33152448 — intervention group
Group type: COMPARATOR
Intervention: Cumulative dose of prednisone tapered over double the time (long arm)
Number of subjects: 78
Study 33152448 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall relapse rate for both arms
Number of subjects: 78
Study 33152448 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-hoc analysis excluding 30 patients treated with low-dose prednisone maintenance therapy
Number of subjects: 78
Study 33152448 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events, blood pressure, and weight gain
Number of subjects: 78
Study 32216730 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 Gy (over 6 weeks) with cisplatin
Number of subjects: 0
Study 32216730 — intervention group
Group type: COMPARATOR
Intervention: 60 Gy (over 5 weeks) alone
Number of subjects: 0
Study 32216730 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 Gy plus cisplatin
Number of subjects: 0
Study 32216730 — intervention group
Group type: COMPARATOR
Intervention: cetuximab
Number of subjects: 0
Study 35622854 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (500,000 IU single oral dose)
Number of subjects: 218
Study 35622854 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218
Study 34352415 — intervention group
Group type: EXPERIMENTAL
Intervention: Anger Management Program
Number of subjects: 43
Study 34352415 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 43
Study 32187881 — intervention group
Group type: EXPERIMENTAL
Intervention: Licogliflozin 50 mg twice daily
Number of subjects: 75
Study 32187881 — intervention group
Group type: EXPERIMENTAL
Intervention: Licogliflozin 150 mg once daily
Number of subjects: 75
Study 32187881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 34837648 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dexamethasone (8 mg once daily)
Number of subjects: 0
Study 34837648 — intervention group
Group type: COMPARATOR
Intervention: Intermediate-dose dexamethasone (8 mg twice daily)
Number of subjects: 0
Study 34837648 — intervention group
Group type: COMPARATOR
Intervention: High-dose dexamethasone (8 mg thrice daily)
Number of subjects: 0
Study 36345013 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone treatment
Number of subjects: 180
Study 36345013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 35353960 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Number of subjects: 1181
Study 35353960 — intervention group
Group type: COMPARATOR
Intervention: Control plasma
Number of subjects: 1181
Study 34708640 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Traditional Chinese and Western Medicine
Number of subjects: 860
Study 34708640 — intervention group
Group type: COMPARATOR
Intervention: Control group treated according to Western Medicine guidelines
Number of subjects: 860
Study 32186587 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Flow Nasal Cannula (HFNC) Oxygen Therapy
Number of subjects: 65
Study 32186587 — intervention group
Group type: COMPARATOR
Intervention: Conventional Oxygen Therapy
Number of subjects: 65
Study 34887325 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose prednisolone
Number of subjects: 0
Study 34887325 — intervention group
Group type: COMPARATOR
Intervention: Low-dose prednisolone
Number of subjects: 0
Study 33609072 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin (10 mg once daily)
Number of subjects: 500
Study 33609072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study 32742520 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus patients
Number of subjects: 0
Study 32742520 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals (control group)
Number of subjects: 0
Study 35813251 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide (ENZ)
Number of subjects: 203
Study 35813251 — intervention group
Group type: COMPARATOR
Intervention: Abiraterone plus Prednisolone (ABI)
Number of subjects: 203
Study 32639389 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dexmedetomidine 0.2 μg·kg‐1 (group LD)
Number of subjects: 90
Study 32639389 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose dexmedetomidine 0.5 μg·kg‐1 (group HD)
Number of subjects: 90
Study 32639389 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline, group P)
Number of subjects: 90
Study 32971163 — intervention group
Group type: EXPERIMENTAL
Intervention: Myrrh extract sitz-bath (10-min, twice a day for 1 week)
Number of subjects: 90
Study 32971163 — intervention group
Group type: EXPERIMENTAL
Intervention: Frankincense extract sitz-bath (10-min, twice a day for 1 week)
Number of subjects: 90
Study 32971163 — intervention group
Group type: COMPARATOR
Intervention: Betadine sitz-bath (10-min, twice a day for 1 week)
Number of subjects: 90
Study 32020410 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with elevated ApoB levels
Number of subjects: 182
Study 32020410 — intervention group
Group type: COMPARATOR
Intervention: Women with elevated ApoB levels
Number of subjects: 182
Study 35084881 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-feedback Intervention to promote Positive Parenting and Sensitive Discipline (VIPP-SD)
Number of subjects: 514
Study 33505154 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus plantarum Dad‐13 powder (2 × 10^9 CFU/gram/sachet) for 90 days
Number of subjects: 60
Study 33505154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 33505154 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus plantarum Dad‐13 powder
Number of subjects: 60
Study 33505154 — intervention group
Group type: COMPARATOR
Intervention: Probiotic Lactobacillus plantarum Dad‐13 powder and Placebo
Number of subjects: 60
Study 616037650 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mug/day fluocinolone acetonide (FAc)
Number of subjects: 0
Study 616037650 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 0
Study 37904790 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Capener orthosis
Number of subjects: 61
Study 37904790 — intervention group
Group type: EXPERIMENTAL
Intervention: Static progressive belly gutter orthosis
Number of subjects: 61
Study 37904790 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial cast orthosis
Number of subjects: 61
Study 37904790 — intervention group
Group type: COMPARATOR
Intervention: All orthosis types
Number of subjects: 61
Study 37904790 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbreviated Weeks test (WT) assessment
Number of subjects: 61
Study 33228979 — intervention group
Group type: COMPARATOR
Intervention: Control (clinical judgement)
Number of subjects: 96
Study 33228979 — intervention group
Group type: EXPERIMENTAL
Intervention: SPI (surgical pleth index)
Number of subjects: 96
Study 33228979 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI (pupillary pain index)
Number of subjects: 96
Study 33228979 — intervention group
Group type: EXPERIMENTAL
Intervention: NOL (nociception level)
Number of subjects: 96
Study 32349268 — intervention group
Group type: EXPERIMENTAL
Intervention: MyGoals for Healthy Aging
Number of subjects: 0
Study 32349268 — intervention group
Group type: EXPERIMENTAL
Intervention: Delphi method
Number of subjects: 0
Study 34608769 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib in patients with COVID-19
Number of subjects: 134
Study 34608769 — intervention group
Group type: EXPERIMENTAL
Intervention: AAG-PK-Model with AAG concentrations
Number of subjects: 134
Study 34608769 — intervention group
Group type: EXPERIMENTAL
Intervention: Covariate modeling including AAG, age, bodyweight, albumin, CRP, and ICU admission
Number of subjects: 134
Study 36414504 — intervention group
Group type: EXPERIMENTAL
Intervention: IA‐PRP
Number of subjects: 96
Study 36414504 — intervention group
Group type: EXPERIMENTAL
Intervention: IA+IO‐PRP
Number of subjects: 96
Study 36414504 — intervention group
Group type: COMPARATOR
Intervention: IA‐NS
Number of subjects: 96
Study 34360299 — intervention group
Group type: EXPERIMENTAL
Intervention: FaCoT intervention
Number of subjects: 66
Study 34360299 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 66
Study 32593489 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth Care Without a Battle (MCWB) program
Number of subjects: 14
Study 35910688 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (CBT) intervention
Number of subjects: 49
Study 32113466 — intervention group
Group type: EXPERIMENTAL
Intervention: Simparica Trio™ (1.2 mg/kg sarolaner, 24 µg/kg moxidectin, 5 mg/kg pyrantel)
Number of subjects: 0
Study 32113466 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarolaner-alone (1.2 mg/kg)
Number of subjects: 0
Study 32113466 — intervention group
Group type: COMPARATOR
Intervention: Moxidectin-alone (24 µg/kg)
Number of subjects: 0
Study 32113466 — intervention group
Group type: COMPARATOR
Intervention: Pyrantel-alone (5 mg/kg)
Number of subjects: 0
Study 32113466 — intervention group
Group type: EXPERIMENTAL
Intervention: Simparica Trio™
Number of subjects: 0
Study 36045484 — intervention group
Group type: EXPERIMENTAL
Intervention: LY06006 (60 mg)
Number of subjects: 168
Study 36045484 — intervention group
Group type: COMPARATOR
Intervention: Denosumab (60 mg)
Number of subjects: 168
Study 33168433 — intervention group
Group type: EXPERIMENTAL
Intervention: EluNIR™ ridaforolimus‐eluting stent (RES)
Number of subjects: 1910
Study 33168433 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolute™ zotarolimus‐eluting stent (ZES)
Number of subjects: 1910
Study 33168433 — intervention group
Group type: COMPARATOR
Intervention: Both RES and ZES
Number of subjects: 1910
Study 34463234 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) and sertraline (SERT)
Number of subjects: 99
Study 34463234 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavioural therapy (CBT) and pill placebo
Number of subjects: 99
Study 35962142 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged (week‐long) daily administration of the SSRI citalopram
Number of subjects: 0
Study 35962142 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute (single‐dose) administration of the SSRI citalopram
Number of subjects: 0
Study 35962142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33377959 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed fluid therapy
Number of subjects: 283
Study 33377959 — intervention group
Group type: COMPARATOR
Intervention: Standard fluid therapy
Number of subjects: 283
Study 34139041 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Chemoradiotherapy (NCRT)
Number of subjects: 83
Study 34139041 — intervention group
Group type: EXPERIMENTAL
Intervention: Definitive Chemoradiotherapy (DCRT)
Number of subjects: 83
Study 34139041 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Chemoradiotherapy (NCRT) followed by surgery
Number of subjects: 83
Study 34239129 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteins implicated in neurological diseases (identified through Mendelian randomization)
Number of subjects: 0
Study 34239129 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid
Number of subjects: 0
Study 34239129 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma
Number of subjects: 0
Study 34239129 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain
Number of subjects: 0
Study 32766304 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic Regression (LR) model with different adjusted weights
Number of subjects: 1779
Study 32766304 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic Regression (LR) model
Number of subjects: 1779
Study 35545584 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii combined with triple therapy for 14 days and triple therapy for 10 days
Number of subjects: 497
Study 35545584 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth quadruple therapy for 10 days
Number of subjects: 497
Study 35545584 — intervention group
Group type: COMPARATOR
Intervention: Standard triple therapy for 10 days
Number of subjects: 497
Study 32318736 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 32929463 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-targeted treat‐to‐target strategy
Number of subjects: 171
Study 32929463 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline MRI osteitis
Number of subjects: 171
Study 32929463 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline tenosynovitis
Number of subjects: 171
Study 32929463 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 171
Study 32929463 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender
Number of subjects: 171
Study 32929463 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tender joint count and low patient visual analogue scale pain and global
Number of subjects: 171
Study 32929463 — intervention group
Group type: COMPARATOR
Intervention: Conventional synthetic DMARDs
Number of subjects: 171
Study 32118723 — intervention group
Group type: EXPERIMENTAL
Intervention: LISA (less invasive surfactant administration via gastric tube)
Number of subjects: 97
Study 32118723 — intervention group
Group type: COMPARATOR
Intervention: INSURE (intubation-surfactant-extubation)
Number of subjects: 97
Study 34551907 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypomethylating agents (Azacitidine and Decitabine)
Number of subjects: 0
Study 34551907 — intervention group
Group type: COMPARATOR
Intervention: Investigational agents (less active)
Number of subjects: 0
Study 34551907 — intervention group
Group type: COMPARATOR
Intervention: Cytostatic agents
Number of subjects: 0
Study 34551907 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive care
Number of subjects: 0
Study 34551907 — intervention group
Group type: EXPERIMENTAL
Intervention: Agents manipulating pyrimidine metabolism
Number of subjects: 0
Study 32585670 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucroferric oxyhydroxide (SFOH) or sevelamer carbonate (sevelamer) for 52 weeks
Number of subjects: 497
Study 32585670 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (pooled treatment groups)
Number of subjects: 497
Study 35695671 — intervention group
Group type: EXPERIMENTAL
Intervention: Colored indicator under glove
Number of subjects: 476
Study 35695671 — intervention group
Group type: COMPARATOR
Intervention: Regular outer glove
Number of subjects: 476
Study 32941737 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketone monoester (KME) supplement (0.45 mL/kg)
Number of subjects: 19
Study 32941737 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 32755265 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-narrative therapy (4 sessions)
Number of subjects: 19
Study 32755265 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 19
Study 32977253 — intervention group
Group type: EXPERIMENTAL
Intervention: AS1000 group (L‐arginine, 1 g; folate, 200 μg)
Number of subjects: 120
Study 32977253 — intervention group
Group type: EXPERIMENTAL
Intervention: AS2000 group (L‐arginine, 2 g; folate, 400 μg; vitamin E, 10 mg)
Number of subjects: 120